The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma.
Young Saing Kim
No relevant relationships to disclose
Moon Ki Choi
No relevant relationships to disclose
Jung Yong Hong
No relevant relationships to disclose
Chi Hoon Maeng
No relevant relationships to disclose
Soonil Lee
No relevant relationships to disclose
In Gyu Hwang
No relevant relationships to disclose
Sang-Cheol Lee
No relevant relationships to disclose
Jong-Mu Sun
No relevant relationships to disclose
Se Hoon Park
No relevant relationships to disclose
Jeeyun Lee
No relevant relationships to disclose
Ho Yeong Lim
No relevant relationships to disclose